Novome-Bio-Logo-RGB

Engineering
Living Medicines
for Chronic Diseases

We don’t discover drugs.

We build them.

The future of medicine is cellular. We engineer cell therapies to outsmart chronic diseases. Therapies that are precise, extensible, and act symbiotically with the patient to achieve long-term health. Beyond smart, our therapies are alive.

We don’t discover drugs.

We build them.

The future of medicine is cellular. We engineer cell therapies to outsmart chronic diseases. Therapies that are precise, extensible, and act symbiotically with the patient to achieve long-term health. Beyond smart, our therapies are alive.

GEMMs: Genetically Engineered Microbial Medicines

The first platform for colonizing the gut with engineered microbes.

The microbes in our gut are living pharmacies, producing and consuming many molecules that impact our health. Novome’s unique synthetic biology tools allow us to plug into this ecosystem and deliver precise activities to treat chronic diseases.

Founded on pioneering technology from Stanford University, our proprietary platform enables controllable engraftment of GEMMs in the gut for sustained and truly effective therapies.

Engineered

We engineer bacterial strains to perform therapeutic functions to address a wide variety of diseases

Colonizing

Our microbes colonize the gut for an extended period of time at a predictable abundance

Controllable

Colonization is maintained and tuned with a daily dose of a prebiotic polysaccharide

Engineered

We engineer bacterial strains to perform therapeutic functions to address a wide variety of diseases

Colonizing

Our microbes colonize the gut for an extended period of time at a predictable abundance

Controllable

Colonization is maintained and tuned with a daily dose of a prebiotic polysaccharide

Our Advantages

The Ideal Modality for Treating Chronic Diseases

Chronic diseases are complicated. Treatment shouldn’t be.

Novome’s platform addresses areas where current therapeutic approaches struggle, enabling multiple targets to be engaged in a dynamic fashion with simple, non-invasive dosing. Manufacturing an intelligent, universal therapeutic is possible with GEMMs.

Well-defined Mechanisms of Action

Our therapies utilize well-studied, highly-abundant gut microbes, programmed with targeted therapeutic activities.

Tunable Treatment

Treatment is tailored to specific conditions by tuning expression of each therapeutic activity.

Convenient Delivery

GEMMs are designed to controllably expand in the gut of any patient, enabling small, oral doses of a universal strain.

Safe and Non-invasive

The gut is our body’s natural interface with foreign cells, making it the ideal site to deploy long-term cell therapies.

Press

Pipeline

The path to living medicines.

Our pipeline targets a variety of diseases based on clinical need and regulatory endpoints, including programs that are both independent and partnered. We focus on diseases with clear, mechanistic etiology that are readily addressed with defined activities.

Our lead program in enteric hyperoxaluria, NOV-001, demonstrated safety and controllable engraftment in a Phase 1 study in healthy volunteers. It is currently being studied in a placebo-controlled, randomized Phase 2a study in patients with enteric hyperoxaluria.

IndicationsPhase
DiscoveryPreclinicalIND-EnablingPhase 1Phase 2
Enteric Hyperoxaluria
Phase 2
Irritable Bowel Syndrome
Preclinical
IBD
Discovery
In Partnership with
In Partnership with Genentech
Discovery
Immuno Oncology
Discovery
NOV-001
Enteric Hyperoxaluria
Irritable Bowel Syndrome
In Partnership with
In Partnership with Genentech
IBD
Immuno Oncology

Our People

Blake Wise
CEO
he/him
Will DeLoache
Will DeLoache
CSO, Co-Founder
he/him
Bill McLeod
CFO
he/him
Lachy McLean
CMO
he/him
Wes Whitaker
Weston Whitaker
VP of Research, Co-Founder
he/him
Liz Shepard
Liz Shepherd
Head of People, Co-Founder
she/her
Zachary Russ
Zachary Russ
Principal Scientist, Co-Founder
he/him
Mark Backman
Senior Software Engineer
he/him
Zack Basham
Research Associate I
he/him
Brooks Bond-Watts
Senior Scientist
he/him
Polina Bukshpun
Director, Clinical Operations
she/her
Areta Buness
Research Associate II
she/her
Justin De Leon
Scientist I
he/him
John Dueber
John Dueber
Sr Director, Synthetic Biology
he/him
Jake Flood
Scientist I
he/him
Jeanette Gehrig
Scientist II
she/her
Caroline Gillis
Scientist I
she/her
Janeth Godoy
Research Associate II
she/her
John Green
Research Associate I
he/him
Ada Huang
Research Associate II
she/her
Sonia Jaidka
Lab Manager
she/her
Kelsey Jensen
Clinical Trial Manager
she/her
Tim Kao
Research Associate I
he/him
Sydney Kaufman
Office Manager
she/her
Hanna Kim
Research Associate I
she/her
Se Kim
Research Assistant
she/her
Marci Kindle
Research Associate I
she/her
Frank King
Director, Drug Product Development
he/him
Kathy Lam
Scientist I
she/her
Mike Lee
AD, Informatics
he/him
Alexander Louie
Scientist II
he/him
Bonnie Mak
Research Associate I
she/her
Coyote Marin
Senior Software Engineer
they/them
Lindsay Piette
Research Associate I
she/her
Lauren Popov
Director, Translational Biology
she/her
Leo Ramirez
Research Associate I
he/him
Harneet Rishi
Harneet Rishi
Scientist II
he/him
Ricky Robinson
Research Associate I
he/him
Karina Rodriguez
Laboratory Assistant
she/her
Kevin Roelofs
AD, Strain Process Development
he/him
Karina Sharma
Research Associate I
she/her
Peter Spanogiannopoulos
Senior Scientist
he/him
Jessica Tan
Research Associate II
she/her
Tariq Warsi
Head of Tech Ops
he/him
Lane Weaver
Lane Weaver
Head of Business Development
he/him
Katie Wilson
AD, In Vivo Research
she/her
David Zong
Scientist I
he/him
Blake Wise
CEO, Board of Directors
Will DeLoache
Will DeLoache, PhD
CSO, Board of Directors
Kiersten Stead, PhD
Board of Directors
Andy Schwab
Andy Schwab
Board of Directors
Dan Janney
Board of Directors
Zachary Hornby
Board of Directors
Dave Cook, PhD
Board of Directors
Justin Sonnenburg
Justin Sonnenburg, PhD
Co-Founder, Scientific Advisory Board
John Dueber
John Dueber, PhD
Scientific Advisory Board
Dean Falb, PhD
Scientific Advisory Board
Eric Martens, PhD
Scientific Advisory Board
Alan Pao
Alan Pao, MD
Scientific Advisory Board

Investors

Careers

At Novome, we are looking for curious and creative people to join our team. Those willing to question the status quo to drive the future of precision therapeutics.

We are located just off the Bay Trail in South San Francisco.

Open Positions
 

Careers

At Novome, we are looking for curious and creative people to join our team. Those willing to question the status quo to drive the future of precision therapeutics.

We are located just off the Bay Trail in South San Francisco.

Open Positions